Immune Modulation
In November 2022, Ryvu Therapeutics and BioNTech have entered into a multi-target research collaboration for several small molecule immunotherapy programs.
Key highlights
BioNTech and Ryvu will jointly undertake drug discovery and research projects to develop multiple small molecule programs directed at exclusive targets selected by BioNTech, primarily focused on immune modulation within oncology, with potential applications in other disease areas.
Platform Collaborations
program
indication
discovery
PRECLINICAL
PHASE I
PHASE II
partner
program
Immune
Modulation
indication
Oncology
discovery
PRECLINICAL
PHASE I
PHASE II
partner
Contact
FOR MEDICAL PROFFESIONALS & INVESTIGATORS
If you are a medical professional, an investigator for a RYVU trial, or would like information about becoming an investigator, please contact us at [email protected] or use contact form.
